1. Pink Sheet
  2. >>Biosimilars & Generics

Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity

 
• By Michael Cipriano

US FDA would get an overall increase in funding under the president's fiscal year 2020 budget proposal, although the generic drug industry opposes reforms targeting the 180-day exclusivity clock for first filers.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.

President Trump is proposing another relatively hefty increase in funding for the US FDA in his fiscal year 2020 budget proposal, and perhaps more significantly, the administration is doubling down on its desire to reform the 180-day exclusivity clock for first generics.

The president's budget would include a budget of $6.1bn for FDA, marking a $643m (12%) overall increase over the annualized FY 2019 continuing resolution levels, according to an HHS summary of the budget released March 11

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics